Literature DB >> 15804617

[Individual patient data meta-analyses in head and neck carcinoma: what have we learnt?].

J-P Pignon1, B Baujat, J Bourhis.   

Abstract

Carcinoma of the upper aerodigestive tract (oral cavity, oropharynx, hypopharynx, nasopharynx, larynx) are frequent tumors for which surgery and/or radiotherapy are the main therapeutic agents. The main results of meta-analyses based on the collection of individual patients data are reported: 1) The meta-analysis on chemotherapy, regrouping data of nearly 11,000 patients issued from 63 randomized trials showed an absolute benefit of 4% at five years in overall survival, in favor of chemotherapy (P<0.0001). Most of the benefit was seen with concomitant radiochemotherapy, however with a relatively large heterogeneity in this subgroup of trials. An update of this meta-analysis was performed including 24 additional trials, which confirmed the magnitude of the benefit due to concomitant chemotherapy (8% at 5 years). 2) The meta-analysis on larynx preservation, using induction chemotherapy in larynx and hypopharynx carcinomas. No significant difference was seen between the control arm with total laryngectomy and the larynx preservation approach. 3) The meta-analysis on chemotherapy in nasopharynx carcinomas, from the data of 11 randomized trials including 2722 patients, and comparing the radiotherapy to radio-chemotherapy (1979-2001). The results showed an absolute benefit of 6% at five years in overall survival, in favor of chemotherapy (P<0.0001). Most of the benefit was seen with concomitant radiochemotherapy. 4) Finally, a meta-analysis on altered fractionated RT, compared to conventional RT in 15 randomized trials regrouping 6515 patients. The results showed a small but significant improvement in favor of altered fractionated RT for overall survival and local control with an absolute benefit at five years of 3 and 6%, respectively.

Entities:  

Mesh:

Year:  2005        PMID: 15804617     DOI: 10.1016/j.canrad.2004.11.002

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  8 in total

1.  A Comparative Study on Weekly Versus Three Weekly Cisplatinum Based Chemoradiation in Locally Advanced Head and Neck Cancers.

Authors:  Tapan Kumar Sahoo; Dipti Rani Samanta; Surendra Nath Senapati; Karishma Parida
Journal:  J Clin Diagn Res       Date:  2017-01-01

2.  Tolerance of Chemoradiation in Advanced Head and Neck Cancers: Comparison Between Inpatients and Outpatients.

Authors:  Virender Suhag; B S Sunita; Pankaj Vats; N Chakravarty; Tejas Pandya; Nishant Lohia
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-10-06

3.  Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents.

Authors:  Shadan Ali; Lalee Varghese; Lucio Pereira; Ozlem E Tulunay-Ugur; Omer Kucuk; Thomas E Carey; Gregory T Wolf; Fazlul H Sarkar
Journal:  Cancer Lett       Date:  2009-02-23       Impact factor: 8.679

Review 4.  [Radiotherapy, chemotherapy and target therapy for treatment of head and neck cancer : new developments].

Authors:  R Knecht
Journal:  HNO       Date:  2009-05       Impact factor: 1.284

5.  Long term results of comparison of concurrent low-dose daily cisplatin versus the standard weekly cisplatin with six fractions per week radiotherapy in locally advanced head neck cancer.

Authors:  Pramod Kumar Gupta; Punita Lal; Ranjeet Bajpai; Anshu Goel; Rajan Yadav; Mranalini Verma; Shaleen Kumar
Journal:  South Asian J Cancer       Date:  2016 Apr-Jun

6.  Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.

Authors:  Tejpal Gupta; Jai Prakash Agarwal; Sarbani Ghosh-Laskar; Purvish M Parikh; Anil K D'Cruz; Ketayun A Dinshaw
Journal:  Head Neck Oncol       Date:  2009-06-15

7.  Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma.

Authors:  Dennis L Carter; Lina Asmar; David Barrera; John Caracandas; J Shaker Dakhil; Dean McCracken; Mark A O'Rourke; Richard K Rosenberg; Kristi A Boehm; Des Ilegbodu; Robert L Reid
Journal:  Invest New Drugs       Date:  2008-05-13       Impact factor: 3.651

8.  Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer.

Authors:  Vanita Noronha; Vijay Maruti Patil; Amit Joshi; Manoj Mahimkar; Usha Patel; Manish Kumar Pandey; Arun Chandrasekharan; Hollis Dsouza; Atanu Bhattacharjee; Abhishek Mahajan; Nilesh Sabale; Jai Prakash Agarwal; Sarbani Ghosh-Laskar; Ashwini Budrukkar; Anil K D'Cruz; Pankaj Chaturvedi; Prathamesh S Pai; Devendra Chaukar; Sudhir Nair; Shivakumar Thiagarajan; Shripad Banavali; Kumar Prabhash
Journal:  Oncotarget       Date:  2020-01-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.